PMID- 7517705
OWN - NLM
STAT- MEDLINE
DCOM- 19940808
LR  - 20190920
IS  - 0891-6934 (Print)
IS  - 0891-6934 (Linking)
VI  - 16
IP  - 4
DP  - 1993
TI  - Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy.
PG  - 251-7
AB  - Graves' disease is an autoimmune disorder but the nature of the association 
      between hyperthyroidism and ophthalmopathy is not yet understood. Serum 
      autoantibodies to orbital tissues have previously been identified and the 
      cross-reactivity with orbital and thyroid antigens has been implicated in the 
      development of thyroid-associated ophthalmopathy (TAO). The ophthalmopathy of 
      Graves' disease is remarkable for the hypertrophy of extraocular muscles and 
      proliferation of fibroblasts within the orbit; features which suggest a possible 
      involvement of growth factors. The present study was therefore undertaken to 
      investigate the interaction of IgGs extracted from the sera of patients with 
      Graves' disease, with or without overt ophthalmopathy, with respect to IGF-1 
      receptor binding sites on fibroblasts from human orbital tissue. IGF-1 binding 
      sites were demonstrated on human orbital fibroblast monolayers grown from eye 
      muscle explants. These cells exhibited a population of high affinity IGF-1 
      binding sites (Kd, 0.5nM SEM +/- 0.05). IgG prepared from sera taken from 
      patients with Graves' disease (n = 23) significantly inhibited [125I]IGF-1 
      binding to orbital fibroblasts when compared to IgGs prepared from normal 
      volunteers (n = 13, p < 0.002). It was found that 12 of 23 (52%) patients' IgG 
      samples gave rise to significant levels of inhibition of [125I]IGF-1 binding to 
      orbital fibroblasts. The IgG preparations did not bind directly to IGF-1. This 
      study demonstrates that IgG prepared from patients with Graves' disease with or 
      without overt ophthalmopathy interact with IGF-1 binding sites on orbital 
      fibroblasts whereas IgG from normal subjects had no significant effect.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Weightman, D R
AU  - Weightman DR
AD  - Endocrine Unit, University of Newcastle Department of Medicine, Medical School, 
      Newcastle-Upon-Tyne.
FAU - Perros, P
AU  - Perros P
FAU - Sherif, I H
AU  - Sherif IH
FAU - Kendall-Taylor, P
AU  - Kendall-Taylor P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Autoimmunity
JT  - Autoimmunity
JID - 8900070
RN  - 0 (Autoantibodies)
RN  - 0 (Carrier Proteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Antibody Specificity
MH  - Autoantibodies/blood/*immunology
MH  - Autoimmune Diseases/blood/*immunology
MH  - Binding, Competitive
MH  - Carrier Proteins/*immunology
MH  - Cells, Cultured
MH  - Fibroblasts/immunology
MH  - Graves Disease/blood/*immunology
MH  - Humans
MH  - Immunoglobulin G/blood/*immunology
MH  - Insulin-Like Growth Factor Binding Proteins
MH  - Models, Biological
MH  - Orbit/cytology
MH  - Receptor, IGF Type 1/*immunology
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.3109/08916939309014643 [doi]
PST - ppublish
SO  - Autoimmunity. 1993;16(4):251-7. doi: 10.3109/08916939309014643.